Author's response to reviews

Title: E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.

Authors:

Gwen Jordaan (gwenrobyn@yahoo.com)
Wei Liao (ericliaowei@gmail.com)
Sanjai Sharma (sasharma@mednet.ucla.edu)

Version: 2 Date: 6 September 2012

Author's response to reviews:

Editorial Office September 3, 2012

BMC Cancer

Dear Editorial Office,

We are submitting an article to the journal BMC Cancer for publication. This report is original research and is not under review at any other journal. The title of the article is “E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.” The report highlights the role of HDAC inhibitors in chronic lymphocytic leukemia. These inhibitors are increasingly being used in the treatment of T-cell leukemia and are in clinical trials for other malignancies as well. In our previous studies we have identified loss of expression of E-cadherin in Chronic lymphocytic leukemia specimens and this report describes the re-expression and alteration in splicing of E-cadherin with HDAC inhibitors.

The authors have no conflict of interest to report.

Sincerely,

Sanjai Sharma MD
Assistant Professor Hematology Oncology
UCLA West Los Angeles VA Medical Center
sasharma@mednet.ucla.edu